Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cel...

Full description

Bibliographic Details
Main Authors: Massimo Caracciolo, Sebastiano Macheda, Demetrio Labate, Marco Tescione, Stefano La Scala, Eugenio Vadalà, Rosalba Squillaci, Francesco D’Aleo, Antonella Morabito, Cristina Garreffa, Maria Concetta Marciano, Esther N. Oliva
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
COVID-19
SARS-CoV-2
canakinumab
IL-1
IL-6
cytokine storm
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01942/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01942/full

Similar Items